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The Organisation for Economic Co-operation
and Development (OECD) has undertaken
the validation of the uterotrophic bioassay.
The management of the validation program
and the results of other portions of the valida-
tion program have been described in other
reports (Kanno et al. 2001, 2003). A central
objective of the OECD validation program is
to establish the reliability of standardized pro-
tocols for the uterotrophic bioassay. A demon-
stration of reliability is based on the
transferability of a protocol among laborato-
ries, where the protocol results are repro-
ducible among laboratories (ICCVAM 1997;
OECD 1998). Two aspects of reliability
require demonstration in a validation pro-
gram: a) the assay’s sensitivity, or ability to
respond to and detect positive substances, and
b) the assay’s specificity, or absence of
response to negative substances (ICCVAM
1997; OECD 1998). Additionally, sensitivity
and specificity should be assessed over time
and should include data gathered using coded
or blinded test substances (ICCVAM 1997;
OECD 1998).
The studies in this paper are intended to
demonstrate the reliability of the uterotrophic
bioassay, including its sensitivity and speci-
ﬁcity with coded samples. The test substances
were a potent reference agonist, five weak
estrogen agonists, and a negative test sub-
stance. Four protocols are included in the val-
idation studies to address the two primary
versions of the uterotrophic assay, the intact,
immature, and the adult ovariectomized
(OVX) female rat as well as the primary
routes of administration, oral gavage and sc
injection. A previous article demonstrated the
reproducibility of the dose response of the
reference agonist, 17α-ethinyl estradiol (EE),
with both versions and all protocols (Kanno
et al. 2001). An accompanying article
demonstrates the reproducibility of both ver-
sions and all protocols using dose responses of
the ﬁve weak agonist test substances (Kanno
et al. 2003). Because all laboratories per-
formed the EE dose response separate from
these data, and almost all laboratories per-
formed the weak agonist dose–response and
coded single-dose studies at separate times, a
comparison of the data provides for an assess-
ment of bioassay reproducibility over time.
Materials and Methods
Test substances. Test substances were
obtained and distributed through a central-
ized chemical repository at TNO, Zeist, the
Netherlands. This repository is described in
the accompanying paper, including a full
description of the chemical identities, puri-
ties, and sources (Kanno et al. 2001), with
the exception of the negative test substance,
n-dibutylphthalate (DBP) (CAS no. 84-74-2,
purity 99.9%) which was obtained from
Sigma Aldrich (St. Louis, MO, USA).
Because of the coded nature of this study, the
amounts of test substance needed by each lab-
oratory were calculated for each protocol.
These amounts were preweighed into individ-
ually coded, opaque vials at the central
repository prior to their shipment.
Animal supply, husbandry, and prepara-
tion. The details of how participating labora-
tories obtained animals, the housing and
husbandry conditions, the age of the animals,
compliance with the OECD guidelines on
animal care (OECD 2000) and appropriate
national regulations, and the animal prepara-
tion and observation prior to test substance
administration have been described previously
(Kanno et al. 2001, 2003).
Protocols. The details of the individual
protocols have also been described previously
(Kanno et al. 2001, 2003). Briefly, protocol
A uses intact, immature female rats with dos-
ing by oral gavage for 3 consecutive days.
Protocol B uses intact, immature female rats
with dosing by sc injection for 3 consecutive
days. Protocol C uses young adult OVX rats
as described above with dosing by sc injection
for 3 consecutive days. Protocol D [previ-
ously called protocol C´ (Kanno et al. 2001)]
also uses young adult OVX rats and extends
the sc injection dosing to a total of 7 days.
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The Organisation for Economic Co-operation and Development has completed phase 2 of an
international validation program for the rodent uterotrophic bioassay. This portion of phase 2
assessed the reproducibility of the assay with a battery of positive and negative test substances.
Positive agonists of the estrogen receptor included the potent reference estrogen 17α-ethinyl estra-
diol (EE), and the weak estrogen agonists bisphenol A, genistein, methoxychlor, nonylphenol, and
o,p´-DDT. The negative test substance or nonagonist was n-dibutylphthalate. The test substances
were coded, and prescribed doses of each test substance were administered in 16 laboratories. Two
versions of the uterotrophic assay, the intact immature and the adult ovariectomized female rat,
were tested and compared using four standardized protocols covering both sc and po administra-
tion. Assay reproducibility was compared using a) EE doses identical to those used in phase 1 and
in parallel dose–response studies, b) single doses of the weak agonists identical to one of ﬁve doses
from the dose–response studies, and c) a single dose of the negative test substance. The results
were reproducible and in agreement both within individual laboratories and across the participat-
ing laboratories for the same test substance and protocol. The few exceptions are examined in
detail. The reproducibility was achieved despite a variety of different experimental conditions
(e.g., variations in animal strain, diet, housing protocol, bedding, vehicle, animal age). In conclu-
sion, both versions of the uterotrophic bioassay and all protocols appear robust, reproducible, and
transferable across laboratories and able to detect weak estrogen agonists. These results will be
submitted along with other data for independent peer review to provide support for the validation
of the uterotrophic bioassay. Key words: endocrine disruption, estrogen, rat uterus, uterotrophic.
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preparation, and dosing. For each test sub-
stance, individualized instructions, depending
on the amount to be shipped, were given to
each laboratory. The instructions speciﬁcally
stated the volume of test vehicle to be added
to the coded vials to provide a reference dose
solution for each test substance. Further
instructions were provided to adjust the
administered test volume based on the
recorded body weight (bw) of the animals to
provide the prescribed experimental doses.
Participating laboratories were asked to
have one set of personnel prepare the test sub-
stance dose solutions and administer the
preparations and a second set perform the
necropsy and record the uterine weights. This
was intended to minimize the chances of
working out the code for each test substance.
Material safety data sheets were provided in a
sealed envelope to a nominated person at each
laboratory, who agreed to keep this envelope
sealed except in cases of emergency. A generic
material safety data sheet was prepared and
supplied to cover all test substances so that
the health and safety of personnel at the
laboratory would not be compromised. The
other details of the vehicle, test substance
preparation, and animal-dosing procedures
have been previously described (Kanno et al.
2001, 2003).
Necropsy, dissection, and uterine weight.
As described previously, the animals were
killed humanely 24 hr after the last test sub-
stance administration in the same sequence as
the test substance was administered. The dis-
section of the uterus and the measurement of
wet and blotted uterine weights to the nearest
0.1 mg were performed as described previ-
ously (Kanno et al. 2001, 2003).
Study management and quality control.
The study management and quality control
have been previously decribed. The VMG
requested that the studies be performed under
OECD Good Laboratory Practice (GLP)
guidelines (OECD 2002). However, full GLP
compliance was not a requirement for a labo-
ratory’s participation in the validation pro-
gram, and several of the laboratories did not
perform their studies under GLP. Data were
received, and after an initial statistical analysis
was performed, all laboratories were requested
to audit these raw data and respond to speciﬁc
queries on outliers and questionable data. A
small number of data corrections were made,
and reporting errors on dilutions, samples,
and identity of control groups were either
corrected or clariﬁed.
Statistics. The recording and statistical
procedures, data evaluation by an analysis of
covariance, logarithmic transformation of
uterine data, use of the Dunnett and Hsu
pairwise comparison test, studentized residual
plots, and use of the ratio of the geometric
means of the uterine weights (relative to the
vehicle control) after adjusting for the body
weight of the animal at necropsy with upper
and lower 95% conﬁdence levels have all been
previously described (Kanno et al. 2003).
To draw inferences across laboratories
about the reproducibility of results at a given
dose for each protocol, mixed-effects linear
models were used, where the laboratories were
treated as the random effects. Such an analysis
takes into consideration both between-lab vari-
ability and within-lab variability, and provides
an overall summary of the results. Thus, the
analysis enables the computation of a mean
response to a chemical across labs, and the
lower and the upper 95% confidence limits
under each protocol. This use of mixed-effects
linear models is termed the “global analysis.”
Design of Phase 2 Coded
Single-Dose Studies
The objective of the coded single-dose studies
was to produce the data to assess the repro-
ducibility of the uterotrophic bioassay both
within the same laboratory and across the
multiple, participating laboratories. Further,
the reproducibility was to be assessed over
time and using blinded or coded samples.
Overall design rationale. Three types of
test substances were included: a potent refer-
ence test substance, EE; five weak estrogen
receptor agonists: genistein (GN), methoxy-
chlor (MX), nonylphenol (NP), bisphenol A
(BPA), and 1,1,1-trichloro-2,2-bis(o,p´-
chlorophenyl)ethane or o,p´-DDT (DDT);
and a negative test substance, DBP. A robust
statistical comparison required that identical
doses be selected so that the same prescribed
doses for each test substance were used in
every laboratory.
Two EE doses were selected from phase 1
(Kanno et al. 2001) to generate two additional
sets of data to assess the reproducibility of the
bioassay. The ﬁrst EE dose for a given route of
administration was the first minimally effec-
tive dose in the lower portion of the
dose–response curve that was a statistically sig-
niﬁcant response in all laboratories in phase 1.
The second EE dose was then 0.5-log higher
than the ﬁrst dose, and this second dose had
given responses near or at the maximum uter-
ine response in phase 1. These selected doses
were used as control reference doses as part of
the accompanying dose–response studies
(Kanno et al. 2003) and in these studies as
coded samples. This design produces three
data sets of replicate doses to assess the repro-
ducibility of the uterine response over time.
The selection of the positive weak ago-
nists and a series of five prescribed doses for
each are described in the accompanying paper
(Kanno et al. 2003). The participating labora-
tories were required in the dose–response
studies to use the three intermediate doses,
whereas the lowest and highest of the five
doses were optional. Therefore, the third or
fourth dose in the series was selected for this
coded single-dose study. As a result, two sets
of replicate doses would be available, one
from the dose–response studies and one from
the coded single-dose studies, and would
include all five weak agonists in all four
standardized protocols.
The negative test substance, DBP, was
chosen based on two lines of evidence. First,
DBP does not display binding afﬁnity for the
rat uterine estrogen receptor, i.e., there is no
displacement of bound [3H]17β-estradiol at
concentrations up to 1 mM concentrations in
vitro (Blair et al. 2000). Second, in vivo toxi-
cological studies, with some including gene
activation proﬁles, indicate that DBP does not
elicit responses indicative of an estrogen mode
of action (Ema et al. 2000; Ema and
Miyawaki 2001; Mylchreest et al. 1998, 1999;
Schulz et al. 2001; Zacharewski et al 1998). A
single data set that included data for all four
standardized protocols was judged adequate
for the negative chemical to conserve resources
and animals.
Selected doses. Two reference EE doses
selected were 1 and 3 µg/kg bw/day for oral
gavage and 0.3 and 1 µg/kg bw/day for sc
injection. For the weak estrogen receptor ago-
nists, the selected doses for the oral gavage
studies were 600 mg BPA/kg bw/day, 300 mg
GN/kg bw/day; 300 mg MX/kg bw/day; 250
mg NP/kg bw/day; and 300 mg DDT/kg
bw/day. Doses for the sc injection studies were
300 mg BPA/kg bw/day; 35 mg GN/kg
bw/day; 500 mg MX/kg bw/day; 80 mg
NP/kg bw/day; and 100 mg DDT/kg bw/day.
For the negative test substance, DBP, a limit
dose was selected for each route of administra-
tion: 1,000 mg/kg bw/day for oral gavage and
500 mg/kg bw/day for sc injection.
Results
The coded single-dose studies were performed
by 16 laboratories. Laboratories 6, 7, 9, 10,
and 15, which either participated in phase 1
(Kanno et al. 2001) or the dose–response
studies in phase 2 (Kanno et al. 2003), did not
participate in the coded single-dose studies.
However, their EE results from these studies
were included in the comparison of the EE
results generated in the coded single-dose
studies. Despite the size of this international
study, the actual difﬁculties encountered were
few. For example, laboratories 17 and 19 may
lack results for MX, BPA, GN, or DDT,
because some of these substances were not
administered after these two laboratories expe-
rienced difficulty in solubilization during
dosage preparation. A few laboratories misin-
terpreted the EE dilution instructions, so that
a few dose concentrations were either reversed
or were incorrect (e.g., the high EE dose in
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of the records were able to correct the data for
the reversals. Finally, uterine wall punctures
were reported in three animals in separate lab-
oratories and groups during dissection. The
possible losses of imbibed ﬂuid did not affect
any results.
Mortalities, decreases in body weight or
body weight gain, and clinical signs. Of
1,842 animals administered test substances
in the coded single-dose studies, 42 mortali-
ties were observed in eight laboratories. All
mortalities in the coded single-dose studies
were in protocol A (2 in GN studies, 3 in
MC studies, 3 in DBP studies, 6 in BPA
studies, 8 in DDT studies, and 19 in NP
studies). As with the dose–response experi-
ments, a dose-related pattern of modest
reductions in body weights and diminished
body weight gains was often observed in the
immature animal studies and in the OVX
studies where the dosing was extended to 7
days. Decreases in body weights at terminal
sacrifice approaching or greater than 10%
were observed with NP in most protocol A
studies, DDT in protocol A, BPA in proto-
col D, MX in protocol D, and the high EE
dose in some protocol D studies (data not
shown), indicating that a maximum toler-
ated dose had been exceeded. Clinical signs
were reported in conjunction with the mor-
talities and body weight losses, including
piloerection, crouched positions, and
labored breathing.
Ethinyl estradiol studies. Within each pro-
tocol, the mean increases in the body
weight–adjusted blotted uterine weights of
both the low and high EE doses were repro-
ducible. The low and high EE dose results for
the dose–response and coded single-dose pro-
tocols are shown in Table 1 and Table 2,
respectively, and the phase 1 results have been
previously reported (Kanno et al. 2001). In
protocol A, the results of the three sets of EE
data were reproducible. The blotted uterine
weight increases were statistically signiﬁcant at
both EE doses, and the weights increased in a
dose-related manner. There were two excep-
tions. Laboratory 1 did not achieve statistical
signiﬁcance at the lower 1 µg EE/kg/day dose
in the dose–response studies, but had achieved
statistical signiﬁcance at this dose in phase 1. In
laboratory 13, the ratio of mean uterine weight
of the test substance group relative to the vehi-
cle control group was nearly ﬁve at the lower
EE dose in the coded single-dose studies. The
ratio was a more modest value of 1.5 to 2 in
phase 1 and the dose–response studies. In pro-
tocol B, the results of the three sets of EE data
were reproducible with two exceptions. First,
the ratio of the uterine weight increases in lab-
oratories 9, 15, 18 at the lower EE dose was
3.5 to 5 in phase 2, compared with approxi-
mately 2 in phase 1. Second, laboratory 19
failed to achieve statistical signiﬁcance at either
EE dose. In protocol C, the results of the three
sets of EE data were reproducible with one
exception. Laboratory 19 achieved statistical
signiﬁcance with the low EE dose, but not the
high EE dose, in the coded single-dose studies.
This same laboratory had shown a low respon-
siveness to EE in protocol C in phase 1 (Table
5 and Figure 1C in Kanno et al. 2001). In pro-
tocol D, the results of the three sets of EE data
were reproducible. As noted in phase 1 (Kanno
et al. 2001), the extended dosing in protocol D
again typically led to a further increase in the
blotted uterine weights over protocol C at both
the low and high EE doses, but the increased
number of EE doses also led to decreases in
body weight gains.
Weak agonist studies. The results for the
same BPA dose in the dose–response and
coded single-dose studies are shown in
Table 3. In protocol A, even at a dose of
600 mg BPA/kg/day, the relative uterine
response was very weak and did not exceed a
value of 2 in any laboratory. In the response
distribution from this modest response, five
laboratories failed to achieve statistical signiﬁ-
cance. Although all ﬁve had increased absolute
uterine weights, the 95% lower confidence
level did not exceed 1 as necessary for statisti-
cal signiﬁcance. In three of these laboratories,
animal mortalities occurred, decreasing the
power. In protocol B, at a dose of 300 mg
BPA/kg/day, the mean ratio values of the rela-
tive increase in uterine weight were between
1.5 and 2.8. In this response distribution, 3 of
23 experiments did not achieve statistical sig-
niﬁcance. In laboratory 12, the mean uterine
weight was increased over 30%, but did not
Mini-Monograph | Kanno et al.
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Table 1. Relative increase in uterine weights versus vehicle controls with replicate low EE doses.
Protocol
A B C D
1 µg/kg/day 0.3 µg/kg/day 0.3 µg/kg/day 0.3 µg/kg/day
Lab Coded studiesa Dose responseb Coded studies Dose response Coded studies Dose response Coded studies Dose response
1—1.10 (0.92, 1.32)c,d — 2.17 (1.80, 2.62)* — 1.98 (1.70, 2.30)* — 2.93 (2.38, 3.60)*
— 0.99 (0.77, 1.26)a,d — 2.49 (2.12, 2.93)* — 2.14 (1.88, 2.43)* — 2.75 (2.30, 3.30)*
2 2.78 (2.19, 3.53)* 3.17 (2.52, 3.99)* 2.25 (1.80, 2.82)* 2.11 (1.70, 2.62)* 2.45 (1.87, 3.19)* 2.41 (2.06, 2.81)* 3.31 (2.74, 4.01)* 3.71 (2.91, 4.74)*
3 1.52 (1.24, 1.88)* 2.25 (1.77, 2.86)* 2.42 (1.96, 3.00)* 2.00 (1.68, 2.38)* 2.35 (1.84, 3.02)* 2.43 (2.14, 2.77)* 3.05 (2.40, 3.88)* 2.77 (2.44, 3.14)*
1.53 (1.20, 1.96)* 2.31 (1.89, 2.81)* — 2.96 (2.36, 3.71)* — 2.85 (2.50, 3.26)*
4 2.81 (2.18, 3.61)* 3.20 (2.36, 4.35)* 1.79 (1.34, 2.39)* 2.75 (1.86, 4.06)* — — — —
5 1.36 (1.07, 1.74)* 1.40 (1.04, 1.90)* 2.07 (1.68, 2.55)* See notee —— — —
6— —— 1.59 (1.15, 2.18)* — 2.43 (1.55, 3.82)* — —
7— 2.16 (1.73, 2.69)*f — 1.73 (1.48, 2.01)* — 1.78 (1.47, 2.16)* — 2.45 (1.97, 3.05)*
— 3.15 (2.57, 3.85)*f — 1.79 (1.52, 2.10)* — 2.71 (2.27, 3.24)* — 3.28 (2.48, 4.35)*
8 3.31 (2.73, 4.00)* 3.09 (2.55, 3.73)* 2.99 (2.40, 3.72)* 2.65 (2.37, 2.97)* 2.72 (2.03, 3.63)* 2.16 (1.91, 2.43)* — —
9— 2.19 (1.72, 2.79)* — 4.22 (3.63, 4.91)* — — — 4.14 (3.34, 5.13)*
11 2.88 (2.26, 3.68)* 3.04 (2.42, 3.83)* 3.24 (2.48, 4.24)* 3.50 (2.83, 4.34)* 2.92 (2.47, 3.46)* 3.04 (2.63, 3.51)* 4.82 (3.61, 6.42)* 5.16 (3.65, 7.28)*
12 2.98 (1.47, 6.03)* 2.85 (2.21, 3.67)* 1.32 (0.91, 1.90)d 1.68 (1.11, 2.53)* 2.00 (1.44, 2.77)* 1.95 (1.52, 2.49)* — —
13 4.74 (3.88, 5.80)* 1.44 (1.06, 1.95)* 5.04 (3.67, 6.90)* 1.61 (1.08, 2.42) — — — —
14 2.44 (1.61, 3.70)* 3.11 (2.44, 3.98)* 2.69 (1.97, 3.68)* 2.61 (2.05, 3.32)* — — — —
15 — — — 4.45 (3.46, 5.71)* — — — —
16 — — 1.58 (1.02, 2.46)* — — — — —
17 — — 1.83 (1.29, 2.61)* — — — — —
18 — — 3.51 (2.86, 4.32)* 3.81 (3.23, 4.50)* — — — —
19 — — 0.95 (0.60, 1.50)d — 1.97 (1.62, 2.40)* — — —
20 — — 1.78 (1.36, 2.33)* 1.83 (1.45, 2.31)* — — — —
9/9 13/15 12/14 18/18 6/6 11/11 3/3 9/9
—, laboratory did not perform this particular study. aResults from studies with coded or blinded doses for each substance. bResults from the dose–response studies reported in the
accompanying paper (Kanno et al. 2003). cRatio of geometric means of treated blotted uterine weights to the vehicle control blotted uterine weights after adjusting for the body weights
at necropsy as a covariable (lower 95% conﬁdence limit, upper 95% conﬁdence limit). dThis study did not achieve statistical signiﬁcance. eThis laboratory used po dilution instructions to
use doses of 1 and 3 µg/kg/day. Therefore, no 0.3-µg/kg/day dose was available. fThis laboratory used sc dilution instructions to use doses of 0.3 and 1 µg/kg/day. The 1-µg/kg/day dose
was the actual low EE dose and is reported here. *Level of signiﬁcance, p < 0.05.achieve signiﬁcance. In laboratory 20, little or
no evidence of a response was seen in either
the dose–response or the coded single-dose
studies. In protocol C, the ratio of the mean
treated uterine weight relative to the vehicle
controls was 2.3 to 3.4, and all laboratories in
this response distribution were able to achieve
statistical signiﬁcance. This ratio value for the
adult OVX animals was consistently greater
than for the immature animals in protocol B.
In protocol D, the mean blotted uterine
weights appeared to be increased by the
extended dosing period, and all six laboratories
achieved statistical signiﬁcance.
The results for the same GN dose in the
dose–response and coded single-dose studies
are shown in Table 4. The mean uterine
responses at the selected GN doses relative to
controls were 2 or greater for most laboratories.
All laboratories in their respective response
distributions achieved statistical signiﬁcance in
each protocol. In the case of GN, the imma-
ture animals in protocol B appeared to have a
somewhat higher mean response than the
Mini-Monograph | Uterotrophic bioassay validation: coded single-dose studies
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Table 2. Relative increase in uterine weights versus vehicle controls with replicate high EE doses.
Protocol
AB C D
3 µg/kg/day 1 µg/kg/day 1 µg/kg/day 1 µg/kg/day
Lab Coded studies Dose response Coded studies Dose response Coded studies Dose response Coded studies Dose response
1— 1.50 (1.25, 1.79)*a — 4.19 (3.47, 5.05)* — 3.13 (2.66, 3.67)* — 4.40 (3.45, 5.61)*
— 1.64 (1.29, 2.10)* — 4.07 (3.46, 4.80)* — 3.77 (3.27, 4.35)* — 4.11 (3.36, 5.04)*
2 4.41 (3.47, 5.60)* 4.13 (3.27, 5.22)* 4.42 (3.52, 5.54)* 4.44 (3.60, 5.48)* 3.68 (2.77, 4.88)* 3.19 (2.69, 3.78)* 4.74 (3.88, 5.81)* 4.86 (3.55, 6.64)*
3 2.79 (2.27, 3.44)* 2.55 (2.00, 3.25)* 4.63 (3.74, 5.73)* 3.82 (3.17, 4.60)* 3.54 (2.74, 4.57)* 3.57 (3.06, 4.18)* 4.41 (3.32, 5.87)* 3.67 (3.13, 4.29)*
2.80 (2.20, 3.58)* 3.79 (3.11, 4.63)* — 3.61 (2.84, 4.59)* — 4.04 (3.49, 4.69)*
4 3.70 (2.88, 4.76)* 4.04 (2.97, 5.48)* 3.41 (2.55, 4.56)* 4.52 (3.06, 6.67)* — — — —
5 1.80 (1.40, 2.31)* 1.91 (1.41, 2.59)* 4.15 (3.37, 5.11)* 3.61 (2.91, 4.46)*b —— — —
6— —— 2.30 (1.71, 3.10)* — 3.89 (2.45, 6.17)* — —
7— See notec — 4.06 (3.49, 4.72)* — 3.29 (2.69, 4.01)* — 4.50 (3.53, 5.73)*
——— 4.16 (3.53, 4.90)* — 4.32 (3.55, 5.25)* — 5.67 (4.15, 7.74)*
8 5.02 (4.15, 6.08)* 4.69 (3.88, 5.66)* 4.76 (3.81, 5.95)* 4.96 (4.43, 5.55)* 3.31 (2.47, 4.42)* 2.70 (2.39, 3.05)* — —
9— 5.19 (4.10, 6.58) — 4.26 (3.64, 4.98)* — — — 4.68 (3.66, 5.99)*
11 4.29 (3.36, 5.48)* 4.52 (3.54, 5.78)* 4.26 (3.17, 5.71)* 4.58 (3.70, 5.69)* 3.92 (3.28, 4.68)* 3.97 (3.36, 4.69)* 5.47 (4.14, 7.21)* 5.85 (4.26, 8.05)*
12 See noted 4.68 (3.63, 6.02)* See noted 3.64 (2.43, 5.45)* See noted 3.08 (2.41, 3.94)* —
13 4.66 (3.83, 5.66)* 2.55 (2.05, 3.17)* 5.21 (3.81, 7.12)* 3.44 (2.25, 5.27) — — — —
14 4.20 (2.73, 6.47)* 4.69 (3.74, 5.89)* 4.83 (3.52, 6.63)* 4.55 (3.59, 5.76)* — — — —
15 — — — 4.95 (3.66, 6.69)* — — — —
16 — — 3.29 (2.13, 5.09)* — — — — —
17 — — 3.50 (2.45, 5.00)* — — — — —
18 — — 5.12 (4.18, 6.29)* 5.62 (4.89, 6.47)* — — — —
19 — — 0.80 (0.50, 1.27)e — 0.96 (0.79, 1.16)e —— —
20 — — 2.41 (1.87, 3.11)* 2.38 (1.90, 2.99)* — — — —
8/8 13/13 12/13 19/19 4/5 11/11 3/3 9/9
—, laboratory did not perform this particular study. aRatio of geometric means of treated blotted uterine weights to the vehicle control blotted uterine weights after adjusting for the
body weights at necropsy as a covariable (lower 95% conﬁdence limit, upper 95% conﬁdence limit). bThis laboratory used po dilution instructions to use doses of 1 and 3 µg/kg/day. The
1 µg/kg/day dose was the actual high EE dose and is reported here. cThis laboratory used sc dilution instructions for doses of 0.3 and 1 µg/kg/day. Therefore, no 3 µg/kg/day high EE dose
was performed. dThis laboratory incorrectly diluted the high EE dose in all studies. eThis study did not achieve statistical signiﬁcance. *Level of signiﬁcance, p < 0.05.
Table 3. Relative increase in uterine weights versus vehicle controls with replicate BPA doses.
Protocol
AB C D
600 mg/kg/day 300 mg/kg/day 300 mg/kg/day 300 mg/kg/day
Lab Coded studies Dose response Coded studies Dose response Coded studies Dose response Coded studies Dose response
1 1.11 (0.90, 1.37)a,b — 1.58 (1.21, 2.08)* — 2.61 (2.23, 3.06)* — 3.65 (2.84, 4.68)* —
2 1.45 (1.14, 1.84)* 1.49 (1.25, 1.77)*c 1.77 (1.40, 2.24)* 2.30 (1.88, 2.81)* 2.61 (1.99, 3.42)* 2.79 (2.28, 3.41)* 3.91 (3.21, 4.76)* 3.74 (2.89, 4.84)*
3 1.40 (1.14, 1.73)* — 2.00 (1.62, 2.48)* — 2.89 (2.24, 3.72)* — 3.26 (2.51, 4.24)* —
4 1.36 (1.05, 1.74)* — 1.45 (1.08, 1.94)* — — — — —
5 1.23 (0.95, 1.57)b — 2.02 (1.64, 2.49)* — — — — —
6— —— 1.37 (1.05, 1.79)* — 2.41 (1.79, 3.23)* — —
7— 1.31 (1.03, 1.66)*c — 1.95 (1.64, 2.32)* — 3.44 (2.76, 4.30)* — 3.90 (3.18, 4.78)*
8 1.91 (1.58, 2.31)* — 1.91 (1.53, 2.39)* 1.91 (1.50, 2.43)* 2.89 (2.16, 3.88)* 2.65 (2.16, 3.24)* — —
11 1.41 (1.11, 1.80)* — 1.82 (1.36, 2.44)* — 3.39 (2.85, 4.05)* — 4.05 (3.08, 5.33)* —
12 1.08 (0.43, 2.71)b,d 1.63 (1.29, 2.06)*c 1.60 (1.12, 2.31)* 1.33 (0.88, 1.99)b 2.30 (1.67, 3.18)* 2.72 (2.05, 3.61)* — —
13 1.25 (1.01, 1.56)*d 1.17 (0.79, 1.72)b,c 1.52 (1.11, 2.08)* 1.72 (1.08, 2.76)* — — — —
14 1.50 (0.95, 2.37)b,d — 2.82 (2.05, 3.87)* — — — — —
15 — — — 1.37 (1.03, 1.81)* — — — —
16 — — 2.11 (1.37, 3.22)* — — — — —
17 — — 2.35 (1.64, 3.37)* — — — — —
18 — — 2.32 (1.88, 2.86)* 2.12 (1.81, 2.50)* — — — —
19 — — — — 2.42 (1.99, 2.95)* — — —
20 — — 1.11 (0.86, 1.44)b 0.95 (0.69, 1.32)b —— — —
6/10 3/4 13/14 7/9 7/7 5/5 4/4 2/2
—, laboratory did not perform this particular study. aRatio of geometric means of treated blotted uterine weights to the vehicle control blotted uterine weights after adjusting for the
body weights at necropsy as a covariable (lower 95% conﬁdence limit, upper 95% conﬁdence limit). bThis study did not achieve statistical signiﬁcance. cIn the dose–response studies at
this dose, one animal died in laboratory 2, one in laboratory 7, one in laboratory 12, and one in laboratory 13. dIn the coded single-dose studies at this dose, three animals died in labora-
tory 12, one in laboratory 13, and two in laboratory 14. *Level of signiﬁcance, p < 0.05.OVX animals in protocol C and even in proto-
col D with the extended dosing period.
The results for the same MX dose in the
dose–response and coded single-dose studies
are shown in Table 5. The mean uterine
responses at the selected MX doses relative
to controls were 2 or greater for most labora-
tories, and often exceed 3 in protocols A and
B. All laboratories in their respective
response distributions achieved statistical sig-
nificance in each protocol. In the case of
MX, the immature animals in protocol B
appeared to have a somewhat higher mean
response than the OVX animals in protocol
C and even protocol D with the extended
dosing period.
The results for the same NP dose in the
dose–response and coded single-dose studies
are shown in Table 6. In protocol A, 13 of 14
studies achieved statistical significance at a
dose of 250 mg NP/kg/day. This is at ﬁrst sur-
prising, given that 11 of these laboratories
experienced animal mortalities that reduced
their power of the already small group size of
six. However, the mean relative increase in
uterine weights was no lower than 1.71 in any
study, and the only laboratory that did not
reach statistical signiﬁcance had only two sur-
viving animals and a mean relative increase of
1.97. In the sc protocols, the mean relative
increases in uterine weight at the selected dose
of 80 mg NP/kg/day were more modest, and
greater than 2 in only 6 of 42 studies. In pro-
tocol B, 17 of 24 studies combined from the
coded single-dose and the dose–response sets
achieved statistical signiﬁcance. In protocol C,
8 of 12 studies achieved statistical signiﬁcance.
In protocol D, all NP coded samples achieved
statistical significance with the extended
dosing period.
The results for the same DDT dose in the
dose–response and coded single-dose studies
are shown in Table 7. In protocol A, all 13
studies achieved statistical significance at a
dose of 300 mg DDT/kg/day, as the mini-
mum mean relative increase in uterine weight
was 2.67. In the sc protocols at a dose of
100 mg DDT/kg/day, the relative increase in
uterine weights was considerably lower, with
only 4 of 36 studies greater than 1.5. As a
result, only 6 of 19 studies achieved statistical
signiﬁcance in protocol B, 5 of 11 in protocol
C, and 4 of 6 studies in protocol D with the
extended dosing period.
Dibutylphthalate studies. The results for
the DBP studies are shown in Table 8. In pro-
tocols A and D, none of the 15 DBP-treated
groups were statistically signiﬁcant versus the
vehicle controls. However, in protocol B, the
results of 4 of 14 studies, and in protocol C,
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Table 4. Relative increase in uterine weights versus vehicle controls with replicate GN doses.
Protocol
AB C D
300 mg/kg/day 35 mg/kg/day 35 mg/kg/day 35 mg/kg/day
Lab Coded studies Dose response Coded studies Dose response Coded studies Dose response Coded studies Dose response
1 2.39 (1.94, 2.95)*a 2.22 (1.67, 2.95)* 2.16 (1.64, 2.84)* 2.33 (1.75, 3.10)* 1.67 (1.42, 1.97)* 1.78 (1.46, 2.18)* 2.11 (1.68, 2.65)* 2.20 (1.78, 2.73)*
2 2.47 (1.93, 3.17)*b — 2.95 (2.35, 3.70)* — 2.07 (1.59, 2.70)* — 2.33 (1.93, 2.80)* —
3 2.73 (2.21, 3.36)* — 2.69 (2.17, 3.33)* — 1.66 (1.30, 2.13)* — 1.85 (1.48, 2.32)* —
4 2.58 (2.01, 3.31)* — 2.26 (1.69, 3.03)* — — — — —
5 1.60 (1.25, 2.05)* — 2.31 (1.88, 2.85)* — — — — —
8 3.20 (2.65, 3.88)* 2.96 (2.42, 3.61)* 2.53 (2.03, 3.15)* 2.69 (2.19, 3.30)* 1.95 (1.46, 2.61)* — — —
9— 2.57 (2.03, 3.25)* — 2.57 (2.19, 3.02)* — 1.87 (1.56, 2.23)* — 2.54 (2.15, 2.99)*
11 2.86 (2.25, 3.65)* — 2.38 (1.78, 3.17)* — 1.73 (1.47, 2.05)* — 2.46 (1.93, 3.14)* —
12 3.74 (1.83, 7.62)* 3.47 (2.71, 4.45)* 2.20 (1.53, 3.17)* 2.28 (1.70, 3.05)* 1.57 (1.12, 2.20)* 1.56 (1.09, 2.21)* — —
13 2.64 (2.17, 3.22)* — 2.25 (1.64, 3.07)* — — — — —
14 2.98 (1.93, 4.61)*b — 3.44 (2.50, 4.72)* — — — — —
16 — — 3.21 (2.10, 4.89)* — — — — —
18 — — 2.53 (2.06, 3.11)* — — — — —
20 — — 1.32 (1.02, 1.70)* — — — — —
10/10 4/4 13/13 4/4 6/6 3/3 4/4 2/2
—, laboratory did not perform this particular study. aRatio of geometric means of treated blotted uterine weights to the vehicle control blotted uterine weights after adjusting for the
body weights at necropsy as a covariable (lower 95% conﬁdence limit, upper 95% conﬁdence limit). bIn the coded single-dose studies at this dose, one animal died in laboratory 2 and
one in laboratory 14. *Level of signiﬁcance, p < 0.05. 
Table 5. Relative increase in uterine weights versus vehicle controls with replicate MX doses.
Protocol
AB C D
300 mg/kg/day 500 mg/kg/day 500 mg/kg/day 500 mg/kg/day
Lab Coded studies Dose response Coded studies Dose response Coded studies Dose response Coded studies Dose response
1 2.97 (2.39, 3.71)*a 2.59 (2.13, 3.15)* 2.73 (2.08, 3.58)* 2.47 (1.91, 3.21)* 1.96 (1.67, 2.30)* 2.32 (1.86, 2.89)* 2.23 (1.77, 2.80)* 2.38 (1.76, 3.22)*
2 3.14 (2.47, 4.00)* — 3.01 (2.39, 3.80)* — 2.08 (1.58, 2.73)* — 2.71 (2.21, 3.31)* —
3 2.77 (2.24, 3.41)* 2.94 (2.34, 3.69)*b 2.66 (2.15, 3.29)* 2.98 (2.42, 3.65)* 2.11 (1.64, 2.71)* 2.42 (1.96, 2.98)* 2.67 (2.03, 3.51)* 2.46 (1.98, 3.06)*
4 3.01 (2.34, 3.86)* — 3.33 (2.49, 4.45)* — — — — —
5 3.10 (2.41, 3.99)* — 3.61 (2.93, 4.45)* — — — — —
8 3.71 (3.07, 4.49)* — 2.91 (2.33, 3.63)* — 2.08 (1.54, 2.80)* — — —
11 3.46 (2.67, 4.48)* — 2.39 (1.81, 3.16)* — 3.14 (2.63, 3.75)* — 3.34 (2.55, 4.36)* —
12 3.20 (1.34, 7.61)* 3.98 (3.07, 5.15)* 3.14 (2.18, 4.51)* 3.34 (2.53, 4.40)* 1.49 (1.09, 2.03)* 1.95 (1.45, 2.62)* — —
13 3.31 (2.72, 4.02)* — 2.89 (2.11, 3.96)* — — — — —
14 2.95 (1.94, 4.48)*c 3.46 (2.51, 4.77)* 4.07 (2.97, 5.56)* 3.76 (2.78, 5.09)* — — — —
16 — — 4.29 (2.81, 6.55)* — — — — —
17 — — 3.25 (2.28, 4.63)* — — — — —
18 — — 3.18 (2.59, 3.90)* — — — — —
20 — — 1.76 (1.37, 2.28)* — — — — —
10/10 4/4 14/14 4/4 6/6 3/3 4/4 2/2
—, laboratory did not perform this particular study. aRatio of geometric means of treated blotted uterine weights to the vehicle control blotted uterine weights after adjusting for the
body weights at necropsy as a covariable (lower 95% conﬁdence limit, upper 95% conﬁdence limit). bIn the dose–response studies at this dose, one animal died in laboratory 3. cIn the
coded single-dose studies at this dose, three animals died in laboratory 14. *Level of signiﬁcance, p < 0.05.the results of 1 of 7 studies, achieved statistical
significance. Of these five studies, three had
signiﬁcantly increased blotted uterine weights
when treated with DBP, whereas the other
two had signiﬁcantly decreased blotted uterine
weights when treated with DBP.
Discussion and Conclusions
The OECD is composed of over 20 nations,
and OECD protocols such as the uterotrophic
bioassay are intended for use in all of the
member nations. As such, this validation
study was carried out in 21 laboratories in
nine nations. Funding for the study came
primarily from national regulatory agencies
and industry associations, but several labora-
tories freely contributed their time and effort
to the study. This large, international nature
of the program, however, increased the orga-
nizational and logistical workload. For exam-
ple, the protocol had to be clearly understood
by speakers of a variety of languages for the
procedures to be performed in a similar
manner in all laboratories. Data had to be
recorded in the different laboratories and
provided to an independent statistician in a
accurate, timely, and efficient manner. The
animal husbandry supplies, vehicles, and
reagents, as well as the laboratory animal
themselves, also had to be widely and readily
available. Finally, the central repository had
to deal with international shipments with dif-
ferent customs regulations and laboratory
safety regulations.
The Validation Management Group
addressed these challenges with several efforts.
Both the ovariectomy and uterine dissection
procedures were videotaped, and the video-
tape was distributed to the technical staff of
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Table 7. Relative increase in uterine weights versus vehicle controls with replicate DDT doses.
Protocol
AB C D
300 mg/kg/day 100 mg/kg/day 100 mg/kg/day 100 mg/kg/day
Lab Coded studies Dose response Coded studies Dose response Coded studies Dose response Coded studies Dose response
1 2.70 (2.15, 3.39)*a — 2.05 (1.57, 2.70)* — 1.65 (1.41, 1.93)* — 1.05 (0.83, 1.31)b —
2 3.68 (2.88, 4.71)*c — 1.13 (0.90, 1.42)b — 1.43 (1.09, 1.86)* — 1.21 (1.01, 1.46)* —
3 3.05 (2.45, 3.81)* 2.67 (1.99, 3.59)* 1.18 (0.95, 1.46)b 1.01 (0.83, 1.23)b 1.29 (1.0035d, 1.65)* 1.43 (1.21, 1.69)* 1.14 (0.92, 1.43)b 1.18 (1.03, 1.36)*
4 3.76 (2.91, 4.87)* — 1.57 (1.17, 2.10)* — — — — —
5 2.92 (2.23, 3.83)* 2.71 (1.92, 3.24)* 0.95 (0.78, 1.17)b 1.18 (0.91, 1.54)b —— — —
8 3.87 (3.18, 4.71)* — 1.06 (0.85, 1.32)b — 1.17 (0.87, 1.57)b 1.25 (0.98, 1.59)b ——
11 3.58 (2.79, 4.60)* 3.43 (2.96, 3.98)* 1.03 (0.78, 1.37)b 1.08 (0.87, 1.34)b 1.24 (1.05, 1.47)* — 1.31 (1.03, 1.68)* 1.48 (1.17, 1.87)*
12 See noteb 3.45 (2.41, 4.94)*e 1.50 (1.04, 2.16)* 1.47 (1.11, 1.94)* 0.96 (0.71, 1.31)b 1.31 (0.96, 1.78)b ——
13 4.12 (3.32, 5.12)* — 1.79 (1.31, 2.45)* — — — — —
14 4.26 (2.65, 6.83)*c — 1.17 (0.85, 1.60)b —— — ——
16 — — 1.29 (0.84, 1.97)b —— — ——
17 — — 1.46 (1.02, 2.08)* — — — — —
18 — — 0.98 (0.80, 1.21)b —— — ——
19 — — 1.07 (0.67, 1.69)b — 1.06 (0.87, 1.29)b —— —
20 — — 0.79 (0.61, 1.02)b —— — ——
9/9 4/4 5/15 1/4 4/8 1/3 2/4 2/2
—, laboratory did not perform this particular study. aRatio of geometric means of treated blotted uterine weights to the vehicle control blotted uterine weights after adjusting for the
body weights at necropsy as a covariable (lower 95% conﬁdence limit, upper 95% conﬁdence limit). bThis study did not achieve statistical signiﬁcance. cIn the coded single-dose stud-
ies, all six animals died in laboratory 12, and two animals died in laboratory 14. dWith the lower confidence level number > 1.00, the result is statistically significant. eIn the
dose–response studies at this dose, one animal died in laboratory 12. *Level of signiﬁcance, p < 0.05.
Table 6. Relative increase in uterine weights versus vehicle controls with replicate NP doses.
Protocol
AB C D
250 mg/kg/day 80 mg/kg/day 80 mg/kg/day 80 mg/kg/day
Lab Coded studies Dose response Coded studies Dose response Coded studies Dose response Coded studies Dose response
1 1.71 (1.37, 2.14)*a — 1.65 (1.26, 2.17)* — 1.43 (1.22, 1.68)* — 1.54 (1.23, 1.93)* —
2 2.03 (1.48, 2.77)*b — 1.34 (1.06, 1.68)* — 1.24 (0.95, 1.62)c — 1.86 (1.55, 2.24)* —
3 1.80 (1.43, 2.27)* — 1.81 (1.46, 2.24)* — 1.37 (1.07, 1.76)* — 1.73 (1.37, 2.18)* —
4 1.89 (1.24, 2.88)*b 2.61 (1.69, 4.04)*d 1.45 (1.08, 1.94)* 2.05 (1.44, 2.92)* — — — —
5 1.74 (1.28, 2.35)*b — 1.64 (1.30, 2.07)* — — — — —
6— —— 1.24 (0.91, 1.68)c — 1.16 (0.90, 1.48)c — 2.11 (1.73, 2.58)*
7—2.17 (1.72, 2.74)*d — 1.68 (1.36, 2.08)* — 1.64 (1.32, 2.03)* — —
8 2.89 (2.33, 3.57)*b — 1.32 (1.06, 1.65)* 1.44 (1.15, 1.80)* 1.59 (1.19, 2.13)* 1.17 (0.98, 1.39)c ——
9— 2.17 (1.62, 2.90)* — 1.86 (1.47, 2.36)* — 1.23 (0.99, 1.52)c 1.83 (1.51, 2.21)*
11 2.33 (1.65, 3.28)*b — 2.05 (1.54, 2.73)* — 1.38 (1.16, 1.63)* — 2.02 (1.57, 2.60)* —
12 1.97 (0.73, 5.33)b,c 2.95 (2.02, 4.32)*d 1.71 (1.19, 2.47)* 2.02 (1.49, 2.75)* 1.38 (1.01, 1.90)* 1.33 (1.02, 1.73)* — —
13 2.24 (1.81, 2.78)*b — 1.08 (0.79, 1.48)c —— — ——
14 2.05 (1.17, 3.59)*b — 1.72 (1.26, 2.35)* — — — — —
15 — — — 1.22 (0.91, 1.65)c —— — —
16 — — 1.30 (0.85, 1.99) — — — — —
17 — — 2.49 (1.74, 3.55)* — — — — —
18 — — 1.73 (1.40, 2.14)* 1.93 (1.56, 2.39)* — — — —
19 — — 1.22 (0.76, 1.96)c — 1.40 (1.15, 1.70)* — — —
20 — — 1.07 (0.83, 1.38)c 0.75 (0.51, 1.11)c —— — —
9/10 4/4 11/15 6/9 6/7 2/5 4/4 2/2
—, laboratory did not perform this particular study. aRatio of geometric means of treated blotted uterine weights to the vehicle control blotted uterine weights after adjusting for the
body weights at necropsy as a covariable (lower 95% conﬁdence limit, upper 95% conﬁdence limit). bIn the coded single-dose studies, one animal died in laboratory 2, four animals died
in laboratory 4, two animals died in laboratory 5, one animal died in laboratory 8, two animals died in laboratory 11, four animals died in laboratory 12, one animal died in laboratory 13,
and four animals died in laboratory 14. cThis study did not achieve statistical signiﬁcance. dIn the dose–response studies at this dose, two animals died in laboratory 4, one animal died in
laboratory 7, and three animals died in laboratory 12. *Level of signiﬁcance p < 0.05.all the participating laboratories. The draft
protocols were distributed to all national
authorities and participating laboratories for
comments and inquiries for any ambiguities.
A common electronic spreadsheet was con-
structed and distributed for comment so the
data could be recorded and electronically
transmitted to the independent statistician.
Despite these efforts and preparations,
some laboratories encountered difﬁculty with
certain dose-preparation instructions, two
errors in the spreadsheet itself were later dis-
covered, and the breakage of some vials dur-
ing shipment required their rapid replacement
because of the imminent delivery of immature
animals whose births were timed for protocols
A and B. Given the number of laboratories
and individual studies, these were minor
problems that did not affect the quality or the
success of the results.
It should also be recognized that the
protocols allowed variations in a number of
experimental conditions. These variables
include the choice of rat strain, the laboratory
diet, housing and husbandry practices such as
the use of cage bedding, the administration
vehicle, and to a modest degree, the age of
both immature and OVX animals. The judg-
ment was that rigorous and detailed standard-
ization of all of these variables would constrain
the ability to widely and easily practice the
uterotrophic bioassay in many of the OECD
member nations, where the intended purpose
is as a rapid screening bioassay for a large
number of chemicals. The laboratory speciﬁcs
for most laboratories have been described pre-
viously (Table 1 in Kanno et al. 2001; Table 7
in Kanno et al. 2003) or can be found for the
remaining laboratories in Table 9.
The coded nature of the study also
introduced some difﬁculties. To avoid giving
very specific information that could be used
to identify the coded test substances, broad
general advice was given about dose prepara-
tion. Unfortunately, estrogen receptor ago-
nists and antagonists tend to be hydrophobic
and to have limited solubility. As noted, some
laboratories encountered difﬁculty in solubi-
lizing the test substances, and two laboratories
decided to halt administration of particular
preparations rather than administer apparent
suspensions. This experience also suggests
another source of variation in administered
doses among the participating laboratories.
As with the dose–response studies, there
was a consistent association in the coded sin-
gle-dose studies between the occurrence of
mortalities, reduced body weight gain, and
clinical signs with the weak agonists DDT and
NP in protocol A, and for reduced body
weight gain with the EE high dose, BPA, and
MX in protocol D. The 10% and greater dif-
ferences in body weights between vehicle and
treated animals occurred within just 4 days
(protocols A, B, and C) or 8 days (protocol D)
of treatment initiation, indicating a rapid
onset of systemic toxicity at those doses.
Despite the apparent magnitude of these
insults, the uterine response appeared to
remain undiminished, conﬁrming the under-
lying robustness of this biological response for
estrogen-screening programs.
Overall, for each protocol, the mean
relative increase in uterine weight was repro-
ducible within and among laboratories for
both the dose–response and coded single-dose
studies with each test substance. The
dose–response results for each protocol and
test substance are in the accompanying paper
(Kanno et al. 2003). It is important to distin-
guish between when the results for a given test
substance have been consistently reproduced
within and across laboratories over time from
whether statistical signiﬁcance was consistently
achieved in all or none of the laboratories. The
objective here is the former, the reproducibil-
ity of the bioassay. The results here should be
interpreted by taking into account the follow-
ing considerations. First, several of selected
doses were in the lower regions of a sub-
stance’s dose–response curve (Kanno et al.
2001, 2003). Second, the lower region of the
dose–response curve implies a distribution of
statistically positive and negative responses,
with the ratio between positive and negative
results depending upon the precise dose
employed in the dose response of that particu-
lar substance. That is, the rate of studies lack-
ing statistical significance should rise as the
doses move further down the dose–response
curve for a substance, particularly in the case
of weak agonists when the slope of the dose
response is shallow. Several doses herein were
at or near maximum uterine responses, for
example, the high EE po and sc doses, the GN
and MX po and sc doses, and the DDT po
dose, and these doses consistently achieved sta-
tistical signiﬁcance. Where the selected doses
were increasingly in the lower portion of the
dose–response curve, although the numerical
results were reproducible within and across
laboratories, an increasing number of studies
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Table 8. Relative increase in uterine weights versus vehicle controls with replicate DBP doses.
Protocol
AB C D
Lab 1000 mg/kg/day 500 mg/kg/day 500 mg/kg/day 500 mg/kg/day
1 0.91 (0.74, 1.13)a 0.97 (0.74, 1.28) 1.37 (1.17, 1.61)*b 0.91 (0.73, 1.15)
2 0.99 (0.78, 1.26) 1.04 (0.83, 1.31) 0.99 (0.76, 1.28) 1.03 (0.86, 1.24)
3 1.00 (0.81, 1.23) 1.01 (0.81, 1.25) 0.90 (0.70, 1.15) 1.01 (0.81, 1.26)
4 0.99 (0.77, 1.28) 0.85 (0.64, 1.14) — —
5 1.03 (0.81, 1.32) 1.06 (0.86, 1.31) — —
8 0.98 (0.81, 1.18) 1.00 (0.80, 1.24) 1.24 (0.92, 1.65) —
11 0.95 (0.75, 1.22) 1.39 (1.06, 1.82)*b 0.99 (0.83, 1.16) 1.00 (0.78, 1.28)
12 0.91 (0.38, 2.20) — 0.97 (0.67, 1.40) 0.93 (0.68, 1.26)
13 0.86 (0.69, 1.07) 0.98 (0.72, 1.34) — —
14 0.91 (0.60, 1.38) 1.38 (1.01, 1.89)*b ——
16 — 0.90 (0.59, 1.38) — —
17 — 0.88 (0.62, 1.26) — —
18 — 0.74 (0.6, 0.91)*b ——
19 — 0.75 (0.47, 1.20) 0.84 (0.69, 1.02) —
20 — 0.73 (0.56, 0.96)*b ——
0/10 4/14 1/7 0/5
—, laboratory did not perform this particular study. aRatio of geometric means of treated blotted uterine weights to the
vehicle control blotted uterine weights after adjusting for the body weights at necropsy as a covariable (lower 95% conﬁ-
dence limit, upper 95% conﬁdence limit). bThis study did not achieve statistical signiﬁcance.*Level of signiﬁcance p < 0.05.
Table 9. Details for animals, diet, vehicles, and bedding in laboratories participating only in coded single-dose studies.a
Strain of ratb Animal dietb For oral gavageb For sc injectionb
Lab Immature rats OVX rats Immature OVX Vehicle 1 Vehicle 2 Vehicle 1 Vehicle 2 Bedding
16 Wistar NA Altromin 1324  NA NA NA Peanut oil NA Wood chip - low dust
FORTII
17 Wistar/Han NA Altromin 1324 NA NA NA Peanut oil NA Tapvei bedding
19 CD Sprague-Dawley CD Sprague-Dawley RM1(E) SQC  RM1(E) SQC  NA NA Corn oil Ethanol/corn oil Lignocel grade 4/4 
expanded pellet expanded pellet woodﬂakes (immature)/
none for OVX
aThe details for laboratories participating in the dose–response studies and that may have participated in the coded single-dose studies herein can be found in Table 7 in Kanno et al.
(2003). bDetailed information is available from the corresponding author of this article.failed to achieve a statistically signiﬁcant dif-
ference, for example, the BPA po dose, the NP
sc dose for adult OVX animals, and certainly
the DDT sc dose.
To assess reproducibility, the mean relative
uterine weight increases were calculated in an
overall global analysis (Table 10). The
uterotrophic responses were consistent and
reproducible between the dose–response and
the coded single-dose studies without excep-
tion for every test substance and every proto-
col. The global analysis in Table 10 also shows
subtle test substance–speciﬁc differences in the
protocols that were consistent in both the
dose–response and coded single-dose studies.
Comparing the intact, immature, and adult
OVX versions as protocols B and C, respec-
tively, the adult OVX version appears to be
more responsive with BPA, whereas the intact,
immature version appears to be more respon-
sive with GN and MX. More than doubling
the time of treatment with extended dosing
(protocol D), did increase the response with
BPA, and marginally with GN, MX, and NP.
The global analysis includes the results of all
laboratories, regardless of mortalities in proto-
col A or the possible issues with laboratories 19
and 20 that are discussed below. Except for the
lower means in the coded single-dose, high-
dose EE studies for protocols B and C, no
overall impact of their inclusion was observed.
The data were analyzed for an association
between uterine weights and body weights
and for the variability and power of the wet
and the blotted weights. Although there was
no consistent correlation between uterine
weight and body weight, the data suggest that
body weight is more strongly correlated with
uterine weight in the immature animals than
in the adult OVX animals. As with phase 1
and the dose–response studies, wet uterine
weights were more variable than blotted
weights (Kanno et al. 2001, 2003). The blot-
ted uterine weights in phase 2, again, showed
slightly less interlaboratory and intragroup
variability than wet weights with imbibed
fluid, suggesting that blotted uterine weight
will provide slightly better power for detect-
ing uterotrophic effects than the wet weight.
In 5 of 36 studies, the uterine weights after
DBP treatment were statistically different from
controls, indicating a certain rate of false posi-
tives and negatives will occur. Three sets of
results were statistically higher than the vehicle
groups, a false positive rate of about 8%, and
two were statistically lower. This nearly even
division into higher and lower differences sup-
ports random chance due to variability about
the baseline. In further support, the margins by
which the respective upper and lower 95% con-
ﬁdence intervals achieved statistical signiﬁcance
were minimal (Table 8). In absolute terms, the
mean relative increase in uterine weight in these
three incidents was just under 40% and sug-
gests a source of variability in the uterine weight
from one group to another. When the raw
body weight and uterine weight data were in
these laboratories were examined, there were no
obvious anomalies or inconsistencies such as
outliers or high standard deviations when com-
pared with other laboratories. When the overall
patterns of these laboratories were assessed, one
(laboratory 20) had the minimum response
with ﬁve of six test chemicals and was below
average for the two EE doses, consistent with its
statistically decreased result. A second (labora-
tory 14) had responses that were the maximum
with two test substances and above average for
the remainder and the EE doses, consistent
with its statistically increased result. The pat-
terns of the other laboratories were unremark-
able. Four of the ﬁve incidents occurred with
immature animals. Although body weights
were randomized, there is the possibility of
group-to-group variations based on a litter-
related effect. The animals used would have
been born on the same day, meaning that the
animals were likely from a limited number of
litters. In fact, some investigators have taken the
precaution to also randomize their groups by
litter (Christian et al. 1998). As the litter of ori-
gin for each individual was not recorded, this
possibility cannot be assessed here. It is clear,
however, that borderline false positives can
occur with the present protocols, and that a
weight-of-the-evidence integration of the
uterotrophic results with other structural, in
vitro, and in vivo data may be necessary for
interpretation. Similarly, false negatives may
also occur, and data to qualify the performing
laboratory and criteria to accept the results may
be necessary (Owens et al. 2003).
The results in three laboratories deserve
comment. These laboratories displayed a
trend toward lower responsiveness to both the
EE and to several weak agonists when com-
pared with other laboratories. The perfor-
mance of laboratory 6 with its high vehicle
control weights and limited responsiveness in
some cases has been previously noted (Kanno
et al. 2003). Here, we also note the lower
general response in this laboratory to the
EE doses in protocol B (Tables 1 and 2).
Laboratory 19 observed no statistically signiﬁ-
cant uterotrophic responses for the test sub-
stances it could formulate or either of the two
EE doses in protocol B (Tables 1, 2, 6, and 7).
The pattern of responses in this laboratory in
protocol C, however, was unremarkable when
compared with other laboratories. A close
examination of the data, including dietary
analyses, has not revealed any apparent reasons
for this lack of responsiveness. Laboratory 20
observed statistical signiﬁcance with both EE
doses, but the relative increases in weight were
somewhat lower than other labs at the low EE
dose and among the lowest at the high EE
dose (Tables 1 and 2). Although statistical sig-
niﬁcance was observed with GN and MX, the
increases in the uterine weights were the low-
est observed in any laboratory (Tables 4 and
5). Statistical signiﬁcance was not observed in
either of the dose–response or the coded sin-
gle-dose studies with either BPA or NP, and
again, the increase in the uterine weights were
the lowest observed in any laboratory (Tables
3 and 6). A review of the data and laboratory
variables ﬁrst indicated that the vehicle control
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Table 10. Global analysis of results.
Protocol
Substance/dose A B C D
BPA mg/kg/day 600 300 300 300
DR 1.41 (1.07, 1.85)a 1.61 (1.00, 2.58) 2.73 (2.07, 3.61) 3.78 (2.98, 4.79)
CSD 1.34 (1.09, 1.66) 1.85 (1.58, 2.16) 2.68 (2.36, 3.04) 3.84 (3.39, 4.35)
DDT mg/kg/day 300 100 100 100
DR 3.13 (2.38, 4.12) 1.16 (0.94, 1.44) 1.33 (1.04, 1.69) 1.31 (1.08, 1.59)
CSD 3.60 (2.94, 4.41) 1.23 (0.97, 1.58) 1.24 (1.00, 1.52) 1.17 (1.06, 1.30)
GN mg/kg/day 300 35 35 35
DR 2.75 (1.98, 3.80) 2.47 (1.82, 3.37) 1.73 (1.45, 2.07) 2.36 (1.61, 3.46)
CSD 2.65 (2.21, 3.18) 2.42 (2.05, 2.86) 1.77 (1.58, 2.00) 2.18 (1.91, 2.49)
MX mg/kg/day 300 500 500 500
DR 3.16 (2.09, 4.79) 3.13 (1.70, 5.75) 2.25 (1.79, 2.83) 2.43 (1.55, 3.83)
CSD 3.21 (2.58, 3.99) 3.03 (2.54, 3.62) 2.07 (1.72, 2.48) 2.62 (2.28, 3.00)
NP mg/kg/day 250 80 80 80
DR 2.40 (1.90, 3.04) 1.51 (1.05, 2.16) 1.29 (1.06, 1.58) 1.96 (1.59, 2.42)
CSD 2.12 (1.72, 2.61) 1.53 (1.26, 1.88) 1.40 (1.24, 1.57) 1.77 (1.58, 1.98)
EE µg/kg/day 1 0.3 0.3 0.3
DR 2.27 (1.71, 3.02) 2.42 (1.86, 3.13) 2.33 (1.97, 2.76) 3.34 (2.79, 4.01)
CSD 2.57 (1.88, 3.51) 2.18 (1.64, 2.90) 2.30 (2.02, 2.62) 3.50 (2.80, 4.37)
EE µg/kg/day 3 1 1 1
DR 3.42 (2.56, 4.57) 5.09 (2.44, 10.62) 3.40 (2.87, 4.03) 4.51 (3.75, 5.43)
CSD 3.78 (2.83, 5.05) 3.56 (2.61, 4.85) 2.67 (1.60, 4.43) 4.87 (4.34, 5.45)
DBP mg/kg/day 1,000 500 500 500
CSD 0.95 (0.77, 1.18) 0.97 (0.80, 1.17) 1.02 (0.84, 1.24) 0.99 (0.91, 1.07)
Abbreviations: CSD, coded single-dose studies; DR, dose–response studies. 
aRatio of geometric means of treated blotted uterine weights to the vehicle control blotted uterine weights after adjusting
for the body weights at necropsy as a covariable (lower 95% conﬁdence limit, upper 95% conﬁdence limit).Mini-Monograph | Kanno et al.
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uterine weights were > 50 mg, which was well
above the 20- to 40-mg range in most other
laboratories. Then, an analysis of laboratory
diets for phytoestrogens found that laboratory
20’s diet had the highest combined total GN
and daidzein levels of > 500 µg/g diet. This
leads to the suspicion that the dynamic range
of the bioassay in this particular case may have
been impaired by the high phytoestrogen con-
tent of the diet (Owens et al. 2003).
Collectively with other observations in the
dose–response studies, these data suggest the
need to monitor the uterine weights of vehicle
control animals, to specify that laboratory
diets have low to modest phytoestrogen levels
(< 350 µg/g diet) (Owens et al. 2003), and to
qualify laboratories with both reference and
weak agonists before performing tests of
unknown substances. In addition, care should
be taken not to exceed the maximum toler-
ated dose, to reduce animal pain, suffering,
and mortalities. The reslts in the current
coded dose study provide additional evidence
that a strong uterine response occurs even in
the presence of severe systemic toxicity. The
robustness of the uterine response in turn
supports its use in a screening assay.
In conclusion, the uterotrophic bioassay
yields reproducible results within the same lab-
oratory and across the participating laborato-
ries over time with a range of test substances
including the EE positive reference substance,
the five weak agonist substances (BPA, GN,
MX, NP, and DDT), and the negative sub-
stance (DBP). The results of the dose–response
and coded single-dose studies are in agreement.
No substantive performance differences were
found between the different versions or their
protocols that would support one version being
consistently superior to another. Therefore,
both the intact immature and OVX versions of
the uterotrophic bioassay and the protocols
herein are judged to be qualitatively equivalent
to one another. Low rates of false negatives and
false positives were observed. The false nega-
tives occurred with very weak agonists (BPA,
DDT, and NP) in the lowest portions of the
their dose–response curves. The false-positive
rate with DBP was just over 8%, with mean
relative weight increases of 30–40%, suggesting
the importance of controlling group-to-group
variations in the baseline and using a weight-
of-the-evidence approach in interpreting very
modest responses. These and other results from
the dose–response studies and the dietary
analyses will be used to develop the draft
OECD test guideline for the uterotrophic
bioassay. These results will be submitted along
with other data for independent peer review to
provide support for the validation of the
uterotrophic bioassay.
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